Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA
3D-QSAR studies of some tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors were performed by comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA) methods to rationalize the structural requirements responsible for the inhibitory activity o...
Gespeichert in:
Veröffentlicht in: | European journal of medicinal chemistry 2006-11, Vol.41 (11), p.1279-1292 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1292 |
---|---|
container_issue | 11 |
container_start_page | 1279 |
container_title | European journal of medicinal chemistry |
container_volume | 41 |
creator | Puntambekar, D.S. Giridhar, R. Yadav, M.R. |
description | 3D-QSAR studies of some tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors were performed by comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA) methods to rationalize the structural requirements responsible for the inhibitory activity of these compounds. The global minimum energy conformer of the template molecule
35, the most active and pharmacokinetically stable molecule of the series, was obtained by simulated annealing method and used to build structures of the molecules in the dataset. The CoMFA model obtained after the removal of outliers produced statistically significant results with cross-validated and conventional correlation coefficients of 0.550 and 0.969, respectively. The combination of steric, electrostatic, hydrogen bond acceptor and hydrophobic fields in CoMSIA gave the best results with cross-validated and conventional correlation coefficients of 0.611 and 0.986, respectively. The predictive ability of CoMFA and CoMSIA were determined using a test set of 24 tricyclicpiperazinyl derivatives giving predictive correlation coefficients of 0.543 and 0.663, respectively, indicating good predictive power. Further the robustness of the model was verified by bootstrapping analysis. Based on the CoMFA and CoMSIA analysis we have identified some key features in the tricyclicpiperazinyl series that are responsible for farnesyltransferase inhibitory activity that may be used to design more potent tricyclicpiperazinyl derivatives and predict their activity prior to synthesis.
Three dimensional quantitative structure–activity relationship studies using comparative molecular field analysis (CoMFA) approach was carried out on a series of tricyclicpiperazinyl derivatives to rationalize the structural requirements for farnesyltransferase inhibitors. |
doi_str_mv | 10.1016/j.ejmech.2006.07.002 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68114080</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523406002303</els_id><sourcerecordid>68114080</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-7b967acba5403ce3389e18ea3053e304820ad8171997a98268030ccdca4dad353</originalsourceid><addsrcrecordid>eNp9kc-O0zAQxi0EYruFN0AoF7gljOP8cS5IVcWyKy3iAHu2ps6EukqcYjuVwivwEn2WPhmuWmlvnGYOv--b0fcx9o5DxoFXn3YZ7QbS2ywHqDKoM4D8BVvwupKpyMviJVtAnou0zEVxw2693wFAWQG8Zje8angjS75gf59sS84HtK2xv5KwpdMRbTBhGkaXoA7mYMKcjN3paMcD9UlwRs-6N3pv9uTwj7Fzn0QLc8DIkk_Qn44dOkt-7oND67uIeUqM3ZqNCaPzyeTPt9bjt7tVEg-fjnH98bB6w1512Ht6e51L9nT35ef6Pn38_vVhvXpMtWggpPWmqWrUGywLEJqEkA1xSSigFCSgkDlgK3nNm6bGRuaVBAFatxqLFltRiiX7ePHdu_H3RD6owXhNfY-WxsmrSnJeQFQtWXEBtRu9d9SpvTMDullxUOcS1E5dSlDnEhTUKpYQZe-v_tNmoPZZdE09Ah-uAHqNfRdT0sY_czKXdVU2kft84SimcTDklNeGrKbWONJBtaP5_yf_ANBnrbQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68114080</pqid></control><display><type>article</type><title>Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Puntambekar, D.S. ; Giridhar, R. ; Yadav, M.R.</creator><creatorcontrib>Puntambekar, D.S. ; Giridhar, R. ; Yadav, M.R.</creatorcontrib><description>3D-QSAR studies of some tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors were performed by comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA) methods to rationalize the structural requirements responsible for the inhibitory activity of these compounds. The global minimum energy conformer of the template molecule
35, the most active and pharmacokinetically stable molecule of the series, was obtained by simulated annealing method and used to build structures of the molecules in the dataset. The CoMFA model obtained after the removal of outliers produced statistically significant results with cross-validated and conventional correlation coefficients of 0.550 and 0.969, respectively. The combination of steric, electrostatic, hydrogen bond acceptor and hydrophobic fields in CoMSIA gave the best results with cross-validated and conventional correlation coefficients of 0.611 and 0.986, respectively. The predictive ability of CoMFA and CoMSIA were determined using a test set of 24 tricyclicpiperazinyl derivatives giving predictive correlation coefficients of 0.543 and 0.663, respectively, indicating good predictive power. Further the robustness of the model was verified by bootstrapping analysis. Based on the CoMFA and CoMSIA analysis we have identified some key features in the tricyclicpiperazinyl series that are responsible for farnesyltransferase inhibitory activity that may be used to design more potent tricyclicpiperazinyl derivatives and predict their activity prior to synthesis.
Three dimensional quantitative structure–activity relationship studies using comparative molecular field analysis (CoMFA) approach was carried out on a series of tricyclicpiperazinyl derivatives to rationalize the structural requirements for farnesyltransferase inhibitors.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2006.07.002</identifier><identifier>PMID: 16919851</identifier><identifier>CODEN: EJMCA5</identifier><language>eng</language><publisher>Oxford: Elsevier Masson SAS</publisher><subject>3D-QSAR ; Antineoplastic agents ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Biological and medical sciences ; CoMFA ; Computer Simulation ; CoMSIA ; Enzyme Inhibitors - chemistry ; Enzyme Inhibitors - pharmacology ; Farnesyl protein transferase ; Farnesyltranstransferase - antagonists & inhibitors ; General aspects ; Medical sciences ; Models, Molecular ; Pharmacology. Drug treatments ; Piperazines - chemistry ; Piperazines - pharmacology ; Quantitative Structure-Activity Relationship</subject><ispartof>European journal of medicinal chemistry, 2006-11, Vol.41 (11), p.1279-1292</ispartof><rights>2006 Elsevier Masson SAS</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-7b967acba5403ce3389e18ea3053e304820ad8171997a98268030ccdca4dad353</citedby><cites>FETCH-LOGICAL-c390t-7b967acba5403ce3389e18ea3053e304820ad8171997a98268030ccdca4dad353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejmech.2006.07.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18287659$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16919851$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Puntambekar, D.S.</creatorcontrib><creatorcontrib>Giridhar, R.</creatorcontrib><creatorcontrib>Yadav, M.R.</creatorcontrib><title>Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>3D-QSAR studies of some tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors were performed by comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA) methods to rationalize the structural requirements responsible for the inhibitory activity of these compounds. The global minimum energy conformer of the template molecule
35, the most active and pharmacokinetically stable molecule of the series, was obtained by simulated annealing method and used to build structures of the molecules in the dataset. The CoMFA model obtained after the removal of outliers produced statistically significant results with cross-validated and conventional correlation coefficients of 0.550 and 0.969, respectively. The combination of steric, electrostatic, hydrogen bond acceptor and hydrophobic fields in CoMSIA gave the best results with cross-validated and conventional correlation coefficients of 0.611 and 0.986, respectively. The predictive ability of CoMFA and CoMSIA were determined using a test set of 24 tricyclicpiperazinyl derivatives giving predictive correlation coefficients of 0.543 and 0.663, respectively, indicating good predictive power. Further the robustness of the model was verified by bootstrapping analysis. Based on the CoMFA and CoMSIA analysis we have identified some key features in the tricyclicpiperazinyl series that are responsible for farnesyltransferase inhibitory activity that may be used to design more potent tricyclicpiperazinyl derivatives and predict their activity prior to synthesis.
Three dimensional quantitative structure–activity relationship studies using comparative molecular field analysis (CoMFA) approach was carried out on a series of tricyclicpiperazinyl derivatives to rationalize the structural requirements for farnesyltransferase inhibitors.</description><subject>3D-QSAR</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>CoMFA</subject><subject>Computer Simulation</subject><subject>CoMSIA</subject><subject>Enzyme Inhibitors - chemistry</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Farnesyl protein transferase</subject><subject>Farnesyltranstransferase - antagonists & inhibitors</subject><subject>General aspects</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperazines - chemistry</subject><subject>Piperazines - pharmacology</subject><subject>Quantitative Structure-Activity Relationship</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc-O0zAQxi0EYruFN0AoF7gljOP8cS5IVcWyKy3iAHu2ps6EukqcYjuVwivwEn2WPhmuWmlvnGYOv--b0fcx9o5DxoFXn3YZ7QbS2ywHqDKoM4D8BVvwupKpyMviJVtAnou0zEVxw2693wFAWQG8Zje8angjS75gf59sS84HtK2xv5KwpdMRbTBhGkaXoA7mYMKcjN3paMcD9UlwRs-6N3pv9uTwj7Fzn0QLc8DIkk_Qn44dOkt-7oND67uIeUqM3ZqNCaPzyeTPt9bjt7tVEg-fjnH98bB6w1512Ht6e51L9nT35ef6Pn38_vVhvXpMtWggpPWmqWrUGywLEJqEkA1xSSigFCSgkDlgK3nNm6bGRuaVBAFatxqLFltRiiX7ePHdu_H3RD6owXhNfY-WxsmrSnJeQFQtWXEBtRu9d9SpvTMDullxUOcS1E5dSlDnEhTUKpYQZe-v_tNmoPZZdE09Ah-uAHqNfRdT0sY_czKXdVU2kft84SimcTDklNeGrKbWONJBtaP5_yf_ANBnrbQ</recordid><startdate>20061101</startdate><enddate>20061101</enddate><creator>Puntambekar, D.S.</creator><creator>Giridhar, R.</creator><creator>Yadav, M.R.</creator><general>Elsevier Masson SAS</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20061101</creationdate><title>Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA</title><author>Puntambekar, D.S. ; Giridhar, R. ; Yadav, M.R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-7b967acba5403ce3389e18ea3053e304820ad8171997a98268030ccdca4dad353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>3D-QSAR</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>CoMFA</topic><topic>Computer Simulation</topic><topic>CoMSIA</topic><topic>Enzyme Inhibitors - chemistry</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Farnesyl protein transferase</topic><topic>Farnesyltranstransferase - antagonists & inhibitors</topic><topic>General aspects</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperazines - chemistry</topic><topic>Piperazines - pharmacology</topic><topic>Quantitative Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Puntambekar, D.S.</creatorcontrib><creatorcontrib>Giridhar, R.</creatorcontrib><creatorcontrib>Yadav, M.R.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Puntambekar, D.S.</au><au>Giridhar, R.</au><au>Yadav, M.R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2006-11-01</date><risdate>2006</risdate><volume>41</volume><issue>11</issue><spage>1279</spage><epage>1292</epage><pages>1279-1292</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><coden>EJMCA5</coden><abstract>3D-QSAR studies of some tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors were performed by comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA) methods to rationalize the structural requirements responsible for the inhibitory activity of these compounds. The global minimum energy conformer of the template molecule
35, the most active and pharmacokinetically stable molecule of the series, was obtained by simulated annealing method and used to build structures of the molecules in the dataset. The CoMFA model obtained after the removal of outliers produced statistically significant results with cross-validated and conventional correlation coefficients of 0.550 and 0.969, respectively. The combination of steric, electrostatic, hydrogen bond acceptor and hydrophobic fields in CoMSIA gave the best results with cross-validated and conventional correlation coefficients of 0.611 and 0.986, respectively. The predictive ability of CoMFA and CoMSIA were determined using a test set of 24 tricyclicpiperazinyl derivatives giving predictive correlation coefficients of 0.543 and 0.663, respectively, indicating good predictive power. Further the robustness of the model was verified by bootstrapping analysis. Based on the CoMFA and CoMSIA analysis we have identified some key features in the tricyclicpiperazinyl series that are responsible for farnesyltransferase inhibitory activity that may be used to design more potent tricyclicpiperazinyl derivatives and predict their activity prior to synthesis.
Three dimensional quantitative structure–activity relationship studies using comparative molecular field analysis (CoMFA) approach was carried out on a series of tricyclicpiperazinyl derivatives to rationalize the structural requirements for farnesyltransferase inhibitors.</abstract><cop>Oxford</cop><pub>Elsevier Masson SAS</pub><pmid>16919851</pmid><doi>10.1016/j.ejmech.2006.07.002</doi><tpages>14</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0223-5234 |
ispartof | European journal of medicinal chemistry, 2006-11, Vol.41 (11), p.1279-1292 |
issn | 0223-5234 1768-3254 |
language | eng |
recordid | cdi_proquest_miscellaneous_68114080 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | 3D-QSAR Antineoplastic agents Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Biological and medical sciences CoMFA Computer Simulation CoMSIA Enzyme Inhibitors - chemistry Enzyme Inhibitors - pharmacology Farnesyl protein transferase Farnesyltranstransferase - antagonists & inhibitors General aspects Medical sciences Models, Molecular Pharmacology. Drug treatments Piperazines - chemistry Piperazines - pharmacology Quantitative Structure-Activity Relationship |
title | Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T10%3A02%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Understanding%20the%C2%A0antitumor%20activity%20of%C2%A0novel%20tricyclicpiperazinyl%20derivatives%20as%C2%A0farnesyltransferase%20inhibitors%20using%20CoMFA%20and%C2%A0CoMSIA&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Puntambekar,%20D.S.&rft.date=2006-11-01&rft.volume=41&rft.issue=11&rft.spage=1279&rft.epage=1292&rft.pages=1279-1292&rft.issn=0223-5234&rft.eissn=1768-3254&rft.coden=EJMCA5&rft_id=info:doi/10.1016/j.ejmech.2006.07.002&rft_dat=%3Cproquest_cross%3E68114080%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68114080&rft_id=info:pmid/16919851&rft_els_id=S0223523406002303&rfr_iscdi=true |